Interim report

January 1 – June 30, 2026

The second quarter in figures

- Net sales were TSEK 15,308 (8,791), +74%, cleared for currency effects +84%.
- The loss after tax was TSEK 28,893 (22,911).
- The loss per share was SEK 2.83 (6.77).
- The cash flow from current operations was negative in the amount of TSEK 33,095 (20,466).
- The gross margin was 52,6% (66.2%).
- Electrode sales volume increased by 118% and was 40,144 (18,398) units. Repeat sales of electrodes to existing customers increased by 75% (incl deliveries to Castle).

The first half-year in figures

- Net sales were TSEK 29,586 (17,648), +68%, cleared for currency effects +79%.
- The loss after tax was TSEK 53,383 (43,592).
- The loss per share was SEK 5.80 (13.69).
- The cash flow from current operations was negative in the amount of TSEK 59,669 (46,467).
- The gross margin was 51.0% (68.4%).
- Electrode sales volume increased by 95% and was 70,556 (36,268) units. Repeat sales of electrodes to existing customers increased by 74% (incl deliveries to Castle).

Important events during the quarter

- Overall sales increased by 74% (+84%, before currency effects). Sales in Germany within the skin cancer segment increased by 18% vs Q2-25 (increased by 18% in local currency). **Sales in the US skin cancer market increased by 80% (88% in local currency)** while the sales within the skin barrier segment increased by 3,231%.
- The gross margin was negatively affected in the quarter by the currency development (negative impact of over 5%), **continued deliveries of products to Castle Biosciences for clinical studies,** increased price on gold and continued investments to ramp up production. Cleared for currency effects and Castle deliveries, the margin was around 70%.
- **SciBase collaboration with Castle has now entered the next phase as the first patient has been included in a new study to assess flare prediction in Atopic Dermatitis.**
- SciBase performed a reverse split 1:100.
- **A new study was published in the peer-reviewed journal *Allergy* demonstrating that results from Nevisense measurements obtained shortly after birth identified children who subsequentially developed atopic dermatitis (AD).**
- A new study was presented demonstrating that Nevisense (EIS) can successfully detect and quantify age-related changes in the skin barrier.
- A study was presented showing that Nevisense can identify damage to the skin barrier from surfactants in household cleaning products.
- **SciBase reaches milestone with over 400,000 tests sold globally.**
- The 2026 AGM was held on May 19th.

Important events after the end of the period

- **SciBase submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) seeking to expand the U.S. indication for Nevisense to include the assessment of Non-Melanoma Skin Cancers (keratinocyte skin cancers).**
- SciBase announced changes in senior management.

Financial overview

THE GROUP	Apr 1 - June 30 2026	Apr 1 - June 30 2025	Jan 1 - June 30 2026	Jan 1 - June 30 2025	July 1, 2025 - June 30, 2026 Rolling-12	Jan 1 - Dec 31 2025
Net sales, SEK ths	15 308	8 791	29 586	17 648	52 400	40 461
Gross margin, %	52,6%	66,2%	51,0%	68,4%	57,5%	67,0%
Equity/Asset ratio, %	41,4%	61,1%	41,4%	61,1%	49,7%	12,8%
Net indebtness, multiple	2,13	0,64	2,13	0,64	1,01	6,84
Cash equivalents, SEK ths	37 153	23 958	37 153	23 958	37 153	22 604
Cashflow from operating activities, SEK ths	-33 095	-20 466	-59 669	-46 467	-97 780	-84 579
Earnings per share (before and after dilution), SEK*	-2,83	-6,77	-5,80	-13,69	-14,64	-24,16
Shareholder's equity per share, SEK*	2,96	9,55	3,28	10,14	4,72	1,85
Average number of shares, 000'*	10 225	3 383	9 211	3 185	6 617	3 604
Number of shares at closing of period, 000'*	10 225	3 663	10 225	3 663	10 225	4 142
Share price at end of period, SEK*	32,50	38,00	32,50	38,00	32,50	29,00
Number of sold electrodes, pieces	40 144	18 398	70 556	36 268	120 468	86 180
Average number of employees	51	35	49	34	44	37

**Recalculated for in June 2026 performed reverse split, 1:100.*

Definitions and a glossary are provided on page 21,



SciBase booth at the FOBI exhibition in Germany

FOBI (Fortbildungswoche für praktische Dermatologie und Venerologie) is one of the key exhibitions in Germany and SciBase participated as usual with a booth.

Comment by CEO Pia Renaudin

" Expanded potential for Nevisense in the US and Castle collaboration entering next phase"

Highlights Q2 2026

- New record sales quarter with sales growth of 74% and cleared for currency effects by 84%.
- Strong US growth, 80% - cleared for currency effects 88%.
- Germany showing good growth, +18% in local currency.
- Next phase in Castle collaboration initiated.
- Accumulated over 400,000 electrodes sold.

Clinical evidence behind success in the US

We have continued to strengthen Nevisense's position in both skin cancer and barrier during the quarter. Several clinical studies and collaborations validate the value Nevisense adds and we see increased interest in the US as well as in other markets.

Total sales amounted to SEK 15.3 (8.8) million, primarily driven by increased growth in the US but also by increased use of the installed base of Nevisense. During the quarter, deliveries of electrodes and Nevisense Go to Castle for the planned joint study, which has now started, were completed. Adjusted for sales to Castle and currency effects, the underlying growth in the quarter amounted to 46%.
In the US, sales increased by a total of 80%, which corresponds to a growth of 88% currency adjusted. Sales are strengthening in Germany after a slightly lower growth in the first quarter and amounted to 18%.



Percentage quarterly sales growth compared to the same quarter in the previous year.

Next phase in Castle collaboration initiated

The first patient is now included in the study conducted by Castle, which aims to predict relapses in atopic dermatitis (AD). The study will use Nevisense Go in a home environment, which allows for longitudinal (continuous) monitoring of the skin barrier function and supports the development of a clinically useful tool for proactive disease management. We have therefore also completed our deliveries to Castle related to this study. Sales to Castle amounted to SEK 3.1 million in the second quarter and SEK 6.3 million for the first six months of the year. Now that the study is initiated, we have started to look at new indications together with Castle and we hope to be able to initiate additional studies towards the end of this year.

Nevisense positioning strenghtened in the US

We have continued to strengthen Nevisense's position in the US market during the second quarter and the interest in Nevisense is high. We participated in a major congress (AAD – American Academy of Dermatology) where we even sold directly at the exhibition. Total sales in the US amounted to SEK 5.5 (3.0) million for the second quarter, which corresponds to a growth of 80%, in local currency an increase of 88%. Sales of electrodes in the US increased by 105% in the quarter, driven by new customers and increased usage.

Our work to broaden the use and ensure reimbursement has continued during the quarter. Among other things, we submitted an application to the FDA regarding NMSC, i.e. non-melanoma skin cancer, which, if approved, would significantly expand the addressable market in the US. To strengthen the conditions for broad reimbursement, we have also submitted an application for a so-called CPT-1 code. This has been made possible by the fact that there is now sufficient documented clinical evidence linked to the use of Nevisense. A CPT-1 code is an important commercial milestone that improves our ability to achieve broad reimbursement and validates Nevisense's clinical value.

Skin barrier

In addition to the collaboration with Castle in the barrier area, several studies are also ongoing, and the increasing amount of clinical data has led to broader interest among both industrial partners and research organizations. During the quarter, we sold electrodes to organizations including the NIH (National Institute of Health) among other things.

Increased growth in Germany

Germany has returned to strong growth after a somewhat weaker start to the year. Total sales amounted to SEK 6.5 (5.5) million, which corresponds to growth of 18%. We have seen both increased demand for Nevisense and increased usage of the existing installed base during the quarter. Interest in the barrier area remains strong and the study regarding atopic dermatitis that we initiated in the first quarter is proceeding according to plan. In July, we participated in FOBI, a major medical congress held every two years with a focus on practical dermatology including dermatosurgery.

Low margin sales and increased costs weigh on gross margin - measures taken

The gross margin in the second quarter was, as expected and previously communicated, still weak. Ongoing investments in capacity to meet future demand, continued deliveries to Castle (low margin on sales to clinical trial) and increased costs had a negative impact. For the second quarter, the gross margin was 52.6% (66.2%). Adjusted for deliveries to Castle that took place in the second quarter and currency effects, the gross margin was approximately 70% (66.2%). We have already started to review our suppliers during the first quarter and have primarily been looking for new suppliers for the production step that includes gold. The measures we have taken will already have a third quarter impact. In addition, the gross margin will be further strengthened as capacity utilization improves.

Process to strengthen financial position initiated

As a result of the strategic investments we pursued during the year to advance the collaboration with Castle and take advantage of the opportunities we have in the US market, cash flow has been negatively affected during the quarter. To ensure deliveries to Castle and the study being conducted, working capital has also increased during the quarter. The board is now evaluating various options to secure our financing, while our main owners have expressed continued support. I am very grateful for the support we have among our existing owners, which gives us the opportunity to continue to advance our positions and deliver on our long-term strategy.

Strategy and organization in place for continued growth

As previously announced, I will step down as CEO of SciBase at the end of the year. It was not an easy decision, but SciBase is now entering a phase where the strategy and organization are set, and the business is on the right track to continue showing strong growth. At the same time, the collaboration with Castle is now being taken to the next level and the American organization's work to obtain reimbursement in the USA is in its final phase. The board has already initiated the process of finding my successor.

We have come a long way in the past year in giving more patients access to better skin cancer diagnostics, while together with Castle we can accelerate studies and opportunities in the barrier area. I am very proud of the fantastic work all employees at SciBase are doing and will continue to do.

Pia Renaudin, CEO
Sundbyberg August 19th, 2026

SCIBASE

SciBase in brief

SciBase - Vision to Value Creation

Vision
Pioneering prediction and prevention in dermatology.

Mission
Products: To develop unique, point-of-care platforms that combine AI (artificial intelligence) with our advanced EIS (electrical impedance spectroscopy).

Providers: To empower healthcare professionals to improve diagnostic accuracy, enable disease monitoring, and facilitate early intervention of skin cancer and skin disorders.

Patients: Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection, and reducing overall healthcare costs.

Value creation
To become the global leader in non-invasive, high-precision skin assessment for cancer detection and skin barrier evaluation, capturing a significant share of a $1billion.

The company has been listed on Nasdaq First North Growth Market exchange since June 2, 2015.

For more information, please visit www.scibase.com

Business model

The company's business model is based on customers initially purchasing a Nevisense platform and consumables (electrodes).

Short facts

- Skin cancer is the most common and fastest-growing form of cancer in the world.
- Melanoma is the most dangerous form of skin cancer with a high mortality rate if not detected early.
- More than 5 million cases of skin cancer detected annually in the US.
- An estimated 234,680 cases of melanoma will be diagnosed in the U.S. in 2026.
- In 2022 skin cancer caused 128,000 deaths.
- SciBase addressable market, in skin cancer alone, is estimate to SEK 4 billion.
- The Nevisense® platform provides physicians with an objective instrument to support better diagnoses.

Certified Advisor (CA)

DNB Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: certifiedadviser@carnegie.se

" *In everyday practice, many pigmented lesions fall into a diagnostic gray zone," said Dr. Hess. "Nevisense adds objective, real-time information beneath the skin's surface, enhancing clinical judgment and supporting more accurate biopsy decisions*". Stephen D. Hess, MD, PhD, FAAD, has published a clinical article highlighting his real-world experience integrating Nevisense into routine melanoma detection. This article was published in The Dermatologist, a leading U.S. clinical dermatology journal.

Skin barrier – a hot topic

- Atopic dermatitis (eczema) is the most common chronic disease with over 200 million patients in the US and Europe and affects about 20% of infants and 7% of adults.
- Skin barrier related diseases such as food allergy and atopic dermatitis (eczema), are a growing problem and there is a large global unmet need for tools for prediction, measurement and management. The market for atopic dermatitis is expected to grow at ~10% annually until 2030.
- Impaired skin barrier is growing with long-term trends such as climate change, increased air pollution, change and loss of biodiversity









The Second quarter

Net Sales

Net sales for the second quarter of 2026 reached a new record high with sales of TSEK 15,308 (8,791), an increase of 74%. Cleared for currency effects sales increased by 84%. The increased sales are mainly due to increased US sales (+80% - +88% in local currency), continued delivery of products to Castle Biosciences for the first clinical study (approximately MSEK 3.1 delivered of the total order value of around MSEK 8 – accumulated the total order has now been delivered). Excluding Castle sales increased by 39% and 46% when cleared for currency effects. Given the nature of research projects sales within the barrier segment continue to vary between quarters, in the period sales (excluding sales to Castle) increased by 76%.

Sales of devices were TSEK 2,148 (627) and sales of electrodes amounted to TSEK 13,158 (8,167) corresponding to about 86% of the turnover reflecting the Company's business model. The total sales within the new skin barrier application were TSEK 3,273 (106) in the period and refers to deliveries to Castle and sales for research.

Sales in Germany in the skin cancer area accounted for 42 (63)% of the sales in the period and increased with 18% vs Q2 2025. In local currency the sales in Germany increased by 18%.

Sales in the US skin cancer segment accounted for 36 (35)% of the sales in the period and increased by 80% (88% in local currency). During this period, several new US customers have been obtained at the same time as existing customers continue to buy electrodes.

Electrode sales in the quarter reached 40,144 (18,398) sold, an increase of 118%. Electrodes sales in volume in the skin cancer segment increased by 19% in Germany, US electrode volumes grew by 105% while barrier volumes increased by 3,904%. Excluding deliveries to Castle sales volumes increased by 37%. Total repeat sales of electrodes increased by 75%.

Operating profit/loss

The operating loss for the period April - June 2026 was TSEK 28,828 (22,358), an increased loss of TSEK 6,470. The increased sales contributed to an improvement in earnings, which were offset by additional sales and marketing expenses through increased investments in the US, increased investments in resources for production capacity and automation resulting in a lower gross margin. SciBase organization in the US was established during the second half of 2024 and has further strengthened during the last 9 months including dedicated resources for reimbursement. The total operating expenses increased in the period by TSEK 8,699 (31%) primarily driven by increased US investments. The operating income was positively affected by currency effects with around MSEK 0.9. The current trend with a strengthening SEK vs mainly the USD will have a positive operating income impact as SciBase currently has higher operating expenses than sales in USD – compared to the average currency rate in Q2-25 the SEK has strengthened with around 8%.

The gross margin in the period was 52,6 (66.2%). Negative currency effects (over 5%), **continued deliveries of products to Castle Biosciences for clinical studies (at a very low/negative margin)**, higher price on gold compared to the beginning of 2025 and continued resource build-up to increase production capacity, which initially affects the yield, have all contributed to the lower margin in the period. SciBase focuses on the margin and the cost for the electrode and in the quarter the electrode gross margin was close to 65 (70)% (lower than usual due to deliveries to Castle – cleared for Castle the margin was 73%) while the margin for device sales was negative - cleared for Castle deliveries it was closer to 0%in the period. The low margin is a consequence of some customers receiving Nevisense free of charge when they buy larger quantities of electrodes. When cleared of currency effects the overall gross margin would be closer to 55.1%. If the margin is also adjusted for deliveries to Castle, it would have been closer to 70%. Overall margin remains highly dependent on electrode production and sales volumes and will vary across quarters.

Sales and marketing expenses increased by TSEK 7,644 and were TSEK 26,133 (18,489). The expenses have increased primarily due to expanded US resources and activities focused on US reimbursement. The US organization has been further expanded during the last 9 months including dedicated reimbursement resources. After the period, a 510(k) application was submitted to FDA to expand the US Nevisense indication to include the assessment of Non-Melanoma Skin Cancers (keratinocyte skin cancers).

Administration expenses for the period were TSEK 3,761 (3,050), an increase of TSEK 711. The increase is primarily attributable to higher legal expenses.

Development expenses for the period were TSEK 6,329 (6,472), a decrease of TSEK 143. The development expenses are focused on investments in production ramp-up and ongoing product development projects.

The financial costs/income have affected the results negatively in the period with MSEK 0.1 (negatively MSEK 0.6). In Q4-25, the Group's accounting for the loan to the American subsidiary SciBase Inc. changed. The loan is treated as part of the net investment in foreign operations in accordance with IAS 21. This means that exchange rate differences that arise when translating the receivable are reported in other comprehensive income instead of in the income statement. The change has been applied retroactively, and comparative figures have been restated.

For Q2-25the restatement improves the result for the period, with a corresponding change in other comprehensive income. Total comprehensive income for the period is unchanged. The effect for the reported period is shown in the table below:

Amounts in KSEK	Q2 2026	Q2 2025
Profit/loss for the period before change	-28 055	-26 589
Effect of net investment classification	-838	3 679
Profit/loss for the period after change	-28 893	-22 911
Comprehensive Income before change	162	4 983
Effect of net investment classification	838	-3 679
Comprehensive Income after change	1 000	1 305
Comprehensive Income for the period (unchanged)	-27 893	-21 606

Cash flow, investments and financial position

At the beginning of the period, cash and cash equivalents were TSEK 71,255 and, at the end of the period, TSEK 37,152.

Cash flow from current operations for the period was negative to the amount of TSEK 33,095 (20,466), of which changes in working capital amounted to negative TSEK 6,322 (positive 114) which was mainly attributable to build-up of inventory and decreased short-term liabilities while in 2025 it was mainly due to increased receivables. Total cash flow for the period was negative to the amount of TSEK 34,228 (negative 10,176). During Q2-2025, the company carried out a directed share issue which net, after issue costs, provided the company with approximately SEK 10.9 million.

Net investment in tangible assets for the period was TSEK 414 (91) and is mainly investment in production tools. Investments in intangible assets for the period were TSEK 0 (0).

Depreciation of tangible assets was charged against earnings for the period to the value of TSEK 1,082 (707) of which TSEK 704 (637) are due to leased assets.

The first half-year

Net Sales

Net sales for the first half-year of 2026 reached a new record high with sales of TSEK 29,586 (17,648), an increase of 68%. Cleared for currency effects sales increased by 79%. The increased sales are mainly due to increased US sales (+79% - +97% in local currency), continued deliveries to Castle Biosciences for the first clinical study (approximately MSEK 6.3 delivered of the total order value of around MSEK 8 – accumulated the total order has now been delivered). Excluding Castle sales increased by 32% and 39% when cleared for currency effects. Given the project-based nature of research sales, sales within the barrier segment continue to vary across quarters. During the period sales (excluding Castle) increased by 13%.

Sales of devices were TSEK 5,780 (1,519) and sales of electrodes amounted to TSEK 23,806 (16,129) corresponding to about 80% of the turnover (slightly lower due to deliveries to Castle of devices) reflecting the Company's business model. The total sales within the new skin barrier application were TSEK 6,746 (333) in the period.

Sales in Germany in the skin cancer area accounted for 54 (64)% of the sales in the period and increased by 9% vs H1 2025. In local currency the sales in Germany increased by 11%.

Sales in the US skin cancer segment accounted for 45 (33)% of the sales in the period and increased by 79% (97% in local currency). During this period, a number of new US customers have been obtained at the same time as existing customers continue to buy electrodes.

Electrode sales in the quarter reached 70,556 (36,268) sold, an increase of 95%. Electrode sales in volume increased by 8% in Germany, 102% in the US while barrier volumes increased by 2,604%. Excluding deliveries to Castle, the volume increased by 26%. Total repeat sales of electrodes increased by 74%.

Operating profit/loss

The operating loss for the period January - June 2026 was TSEK 53,281 (41,936), an increased loss of TSEK 11,345. The increased sales contributed to an improvement in earnings, which was balanced by increased sales and marketing expenses through increased investments in the US, increased investments in resources for production capacity and automation and a lower gross margin. SciBase organization in the US was established during the second half of 2024 and has further strengthened during the last nine months including dedicated reimbursement resources. Total operating expenses increased in the period by TSEK 14,356 (26%) primarily driven by increased US investments. The operating income was positively affected by currency effects with around MSEK 1.7. The current trend with a strengthening SEK vs mainly the USD will have a positive impact on the operating income as SciBase currently has higher operating expenses than sales in USD – compared to the average currency rate in H1-25 the SEK has strengthened with around 8%.

The gross margin in the period was 51.0 (68.4%). Negative currency effects (over 5%), **continued deliveries of products to Castle Biosciences for clinical studies (at a very low/negative margin)**, higher gold prices compared to H1-25 and continued resource build-up to increase production capacity, which initially affects the yield, have all contributed to the lower margin in the period. SciBase focuses on the margin and the cost for the electrode and in the quarter the margin for the electrode was close to 65 (73)% (lower than usual due to deliveries to Castle – cleared for Castle the margin was 72%) while the margin for device sales was negative - cleared for Castle deliveries it was 9%in the period. When cleared of currency effects the overall gross margin would be closer to 54.6%. If the margin is also adjusted for deliveries to Castle, the margin would have been closer to 68%. The overall margin remains very dependent on electrode production and sales volumes and will vary between quarters.

Sales and marketing expenses increased by TSEK 12,360 and were TSEK 46,950 (34,590). The expenses have increased primarily due to increased US resources and activities focused on US reimbursement. During the last nine months the US organization has been further expanded including dedicated reimbursement resources. During the period, the first formal reimbursement application was submitted to a major private insurance company.

Administration expenses for the period were TSEK 7,866 (6,509), an increase of TSEK 1,357. The increase is primarily attributable to the in Q1-26 performed capital raise, QA activities and increased legal expenses.

Development expenses for the period were TSEK 12,609 (12,322), an increase of TSEK 287. The development expenses are mainly driven by increased investments in production ramp-up and ongoing product development projects within which require increased resources.

The financial costs/income have affected the results negatively in the period with MSEK 0.1 (negatively MSEK 1.7). In Q4-25, the Group's accounting for the loan to the American subsidiary SciBase Inc. changed. The loan is treated as part of the net investment in foreign operations in accordance with IAS 21. This means that exchange rate differences that arise when translating the receivable are reported in other comprehensive income instead of in the income statement. The change has been applied retroactively, and comparative figures have been restated.

The effect for H1-25 means an improved result for the period but a corresponding change in other comprehensive income. The comprehensive income for the period is unchanged. The effect for the period is shown in the table below:

Amounts in KSEK	H1 2026	H1 2025
Profit/loss for the period before change	-52 128	-54 100
Effect of net investment classification	-1 256	10 507
Profit/loss for the period after change	-53 383	-43 593
Comprehensive Income before change	-581	11 564
Effect of net investment classification	1 256	-10 507
Comprehensive Income after change	675	1 057
Comprehensive Income for the period (unchanged)	-52 708	-42 536

Cash flow, investments and financial position

At the beginning of the period, cash and cash equivalents were TSEK 22,604 and, at the end of the period, TSEK 37,152.

Cash flow from current operations for the period was negative to the amount of TSEK 59,669 (46,467), of which changes in working capital amounted to negative TSEK 9,566 (negative 5,476) which was mainly attributable to inventory build-up, decreased short-term liabilities and increased receivables while in 2025 it was mainly due to decreased short-term liabilities and increased receivables. Total cash flow for the period was positive to the amount of TSEK 14,761 (positive 12,934). During the period, the company carried out a rights issue which net, after issue costs, provided the company with approximately SEK 76.3 million. During H1-25, three issues were carried out: in the second quarter, a directed issue that netted the company SEK 10.9 million, and in the first quarter of 2025, the company carried out two new issues, a directed issue and a rights issue, which netted the company approximately SEK 49.8 million.

Net investment in tangible assets for the period was TSEK 414 (91). Investments in intangible assets for the period were TSEK 0 (0).

Depreciation of tangible assets was charged against earnings for the period to the value of TSEK 2,076 (1,466) of which TSEK 1,409 (1,313) are due to leased assets.

Other disclosures

Shareholders

At the end of the period, SciBase Holding AB had approximately 2,650 shareholders. Per June 30, the five largest shareholders represented approximately 59.1% of the capital and votes. The total number of shares per June 30, 2026, was 10,225,300. At the 2026 Annual General Meeting, it was decided to carry out a 1:100 share reverse split, which was carried out in June 2026. The largest shareholders as of June 30, 2026, were Ribbskottet AB (21%), Castle Biosciences Inc (20%), Coeli Wealth Management (7%), Ejendal Industries AB (7%) and Avanza Pension AB (5%).

Market overview

SciBase is active within both skin cancer detection and skin barrier assessment. SciBase's Nevisense platform addresses multiple sizeable clinical application areas.

Skin cancer

Skin cancer is believed to be the most common form of cancer in the world. More than 5 million cases of skin cancer are reported every year in the US alone, which is more than all other cancers combined. SciBase estimate its total addressable market potential within melanoma to be around 400 million USD per year or approximately SEK 3.7 billion.

The population of non-melanoma skin cancer patients includes more than ten times the number of patients compared to the melanoma patient population. SciBase estimates that the potential for the use of Nevisense amounts to at least 4 million examinations or tests annually. Given this, non-melanoma skin cancer is estimated to have a total market potential of approximately SEK 1.4 billion annually.

Skin barrier

An exciting application area is skin barrier assessment. The skin barrier stops irritants, allergens etc. from entering the body, and water from leaving. An impaired skin barrier at birth can be a predictor of the development of Atopic Dermatitis (AD) or eczema. The development of AD often precedes the development of other atopic diseases such as food allergies, allergic rhinitis and allergic asthma. The ability to easily detect an impaired skin barrier can help detect, manage and treat atopic diseases before the development of AD. There is a high interest from the research community, and this group is the short-term sales target within the barrier area.

As many as up to 20% of all children and 7% of all adults suffers from atopic dermatitis. The application area includes disease development prediction in infants, diagnostic and therapy selection tests in a clinical setting, and regular tests in the home to monitor and manage the disease. The total number of measurements for all patients with atopic dermatitis could potentially exceed the tens of million per year.

Initially SciBase focuses on the launch of atopic dermatitis in Germany and sales towards researchers.

Employees

At the end of the period, the number of employees amounted to 50 (34), of whom 51 (50)% were women. This includes the production employees at our Uppsala production facility and sales representatives in Germany and the US.

Financing

The Board of Directors regularly reviews the Company's current and projected cash flows to ensure it has sufficient resources to operate the business and execute the strategic plan. The Company's long-term cash requirements depend largely on its ability to successfully commercialize Nevisense. This, in turn, is influenced by several factors, including costs associated with inclusion in insurance systems, reimbursement levels, marketing expenses, and compliance with regulatory requirements.

Based on the strategic plan, the Board determined at the end of 2025 that further capital was needed and initiated a rights issue, completed in January 2026, which raised approximately SEK 80 million before costs. The issue was subscribed to 96.4 percent, which the Board views as a strong vote of confidence from both existing and new shareholders.

The Company remains in an expansion phase, with increasing sales but not yet generating positive cash flow. The Board therefore notes that additional financing will be required to continue implementing the strategic plan. At the end of the second quarter of 2026, the Group's cash amounted to SEK 37.2 million, which the board does not consider to be sufficient to finance the operations during the coming twelve-month period.

The Board notes several positive circumstances that are considered to create good conditions for raising additional capital. These include the strong commercial development during 2025 and the first half of 2026, the strategic partnership with Castle Biosciences, the broadened ownership base and the interest the group is encountering in the capital market. Although the outcome of future capital raises is to some extent beyond the company's control, the Board believes that the opportunities to secure additional financing are good. The Board is continuously evaluating various alternatives to secure the company's long-term financing and is confident that the company's short- and long-term capital needs will be secured.

Transactions with related parties

During the year, the parent Company SciBase Holding AB invoiced TSEK 2,372 (2,372) to the fully owned subsidiary SciBase AB, which corresponds to a 100% of the parent Company's turnover in the period. During the reporting period there were no other transactions with related parties that had any material impact on the Group or Parent Company's position and earnings.

Risks and uncertainty

The principal risks and sources of uncertainty for SciBase include, albeit not exclusively, financial risks, such as the future earnings trend, financing, and currency and credit risks. In addition to market risks, there are also risks associated with SciBase's operations, such as obtaining necessary approval from authorities, product development, patents and intellectual property rights, product responsibility and forward-looking information. Nor are there any guarantees that the Company will be able to secure the financial resources necessary to conduct its operations. Further information on the Company's risk exposure can be found on pages 40-44 of SciBase's 2025 Annual Report.

Parent Company

SciBase Holding AB (publ), corporate identity number 556773-4768, is the Parent Company of the Group. The company was formed in 2009 following a restructuring of the Group. The actual operations are conducted by the fully owned subsidiary SciBase AB.

As per June 30, 2026, there were two employees, the CEO and the CFO. The operations consist of consulting activities for the rest of the Group. The company's main task is of a financial nature – to fund the Group's operational activities.

Net sales for the period reached TSEK 2,372 (2,372). The loss for the period amounted to TSEK 25,956 (36,425). The Company's net sales consist of invoiced consultancy fees to the fully owned subsidiary SciBase AB.

The shareholders' contributions to the fully owned subsidiary SciBase AB are from 2016 and onwards charged to earnings and not booked as a financial tangible asset. The shareholders' contribution expensed during the period was MSEK 20.6 (32.5).

Significant events during the quarter

The collaboration with Castle has now entered into a new phase as in the period the first patient was enrolled in a new study to assess flare prediction in Atopic Dermatitis. The primary objective of the multicenter prospective clinical study is to assess the prediction of flares in atopic dermatitis (AD). This milestone marks a significant step forward in understanding and managing this chronic, inflammatory skin condition, which affects millions of people worldwide.
The study, titled DETECT-AD, the first study through the collaboration with Castle Biosciences, will investigate SciBase method of Electrical Impedance Spectroscopy (EIS) ability to predict the onset of flares in patients with atopic dermatitis. By identifying early signs, the research aims to enable proactive interventions, improve patient quality of life, and reduce the burden of unpredictable flare-ups.

At the Annual General Meeting of SciBase Holding AB (publ) on 19 May 2026, it was resolved on a reverse share split of the Company's shares, whereby one hundred existing shares shall be consolidated into one (1) share (Sw. *sammanläggning 1:100*) (the "Reverse Share Split"). The board of directors was further authorised to determine the record date for the Reverse Share Split. The board of directors has today resolved that the record date for the Reverse Share Split shall be on 5 June 2026. The new number of shares after the reversed split is 10,225,300.

A study was published in the peer-reviewed journal *Allergy* demonstrating that results from Nevisense measurements obtained shortly after birth identified children who subsequentially developed atopic dermatitis (AD). The study was conducted by researchers at the Icahn School of Medicine at Mount Sinai and assessed neonatal skin barrier integrity using Nevisense within the first days of life. Infants who developed atopic dermatitis during their first year had significantly higher neonatal measurements than those who remained disease-free, suggesting that Nevisense may serve as a non-invasive early biomarker of skin barrier dysfunction associated with future atopic dermatitis risk. The conclusion from the study was "Higher EIS scores, suggestive of impaired skin barrier, within the first week of life were significantly associated with development of AD in the first year of life."

During the period a new study was presented at the Society for Investigative Dermatology (SID) Annual Meeting. The study, conducted by prof. Abuabara and Dr. Zhu at UCSF (The University of California, San Francisco), demonstrates that SciBase's proprietary Electrical Impedance Spectroscopy (EIS) technology, featured in the Nevisense platform, can successfully detect and quantify age-related changes in the skin barrier.

A scientific project with the Swiss Institute of Allergy and Asthma Research (SIAF) in Davos, Switzerland was presented in the period. Nevisense and its underlying Electrical Impedance Spectroscopy (EIS) technology were used to show that surfactants in household cleaning products disrupt the human skin barrier.

A significant milestone was achieved in the period with over **400,000 Nevisense tests** sold worldwide.

The annual general meeting hled on May 19th resolved:

- to adopt the profit and loss statement and the balance sheet and the group profit and loss statement and the group balance sheet for the financial year 2025;
- that no dividend shall be paid for the financial year 2025 and that the year's result shall be carried forward;
- to grant the board members and the CEO discharge from liability for the financial year 2025;
- that the board of directors shall consist of four ordinary members without deputy members and that a registered accounting firm shall be elected as auditor;
- that the fees payable to the board of directors for the period until the end of the next annual general meeting shall be SEK 415,000 for the chairman of the board and SEK 150,000 to each of the other ordinary board members (who are not employed by a larger shareholder in the Company) and that fees payable to the auditor are to be paid in accordance with approved invoices;
- for the period until the end of the next annual general meeting, to re-elect Jesper Høiland, Robert Molander, Diana Ferro and Anna Eriksrud as board members, to re-elect Jesper Høiland as

chairman of the board of directors and to elect the auditing firm Öhrlings PricewaterhouseCoopers AB as auditor for the Company, with Magnus Lagerberg as auditor in charge;
- to adopt principles for the appointment of a nomination committee;
- to amend the articles of association and to carry out a reverse share split, whereby one hundred (100) existing shares will be consolidated into one (1) new share (reverse share split 1:100). Following registration of the reverse share split with the Swedish Companies Registration Office, the quota value per share increases from SEK 0.05 to SEK 5.00;
- to implement stock option program consisting of a directed issue of warrants and approval of transfer of warrants for the fulfillment of the Company's obligations under the stock option program; and
- to authorize the board of directors to increase the share capital through issuance of new shares, warrants and/or convertible debentures. Through issuances resolved upon with support from the authorisation – with deviation from the shareholders' preferential rights - the number of shares issued, or number of shares created in connection with exercise of warrants or conversion of convertibles, shall correspond to not more than a 20 per cent dilution of the share capital and the number of shares and votes in the Company after such issue(s).

Significant events after the period

After the period SciBase submitted of a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) seeking to expand the U.S. indication for Nevisense to include the assessment of Non-Melanoma Skin Cancers (keratinocyte skin cancers).

SciBase announced that Pia Renaudin has decided to leave her role as CEO at SciBase. Pia Renaudin has, after almost 3 years as CEO of SciBase Holding AB (publ), informed the Board of her decision to leave the company. She will be taking on a new CEO role elsewhere. Pia Renaudin will remain in her position until the 31st of December 2026.

Consolidated summary Income Statement

SEK 000'	Apr 1 - June 30 2026	Apr 1 - June 30 2025*	Jan 1 - June 30 2026	Jan 1 - June 30 2025*	July 1, 2025 - June 30, 2026 Rolling-12	Jan 1 - Dec 31 2025
Net sales	15 308	8 791	29 586	17 648	52 400	40 461
Cost of goods sold	-7 258	-2 970	-14 511	-5 584	-22 285	-13 357
Gross Profit/Loss	**8 050**	**5 821**	**15 075**	**12 064**	**30 115**	**27 104**
Sales and marketing expenses	-26 133	-18 489	-46 950	-34 590	-86 715	-74 355
Administration expenses	-3 761	-3 050	-7 866	-6 509	-15 435	-14 078
Development expenses	-6 329	-6 472	-12 609	-12 322	-24 139	-23 852
Other operating income	0	0	0	0	6	6
Other operating expenses	-655	-169	-931	-579	-1 591	-1 240
Operating Income	**-28 828**	**-22 358**	**-53 281**	**-41 936**	**-97 758**	**-86 414**
Financial income	187	-503	440	-1 560	2 304	304
Financial expenses	-252	-50	-542	-96	-1 400	-953
Profit/Loss before taxes	**-28 893**	**-22 911**	**-53 383**	**-43 592**	**-96 854**	**-87 063**
Income tax	0	0	0	0	0	0
Profit/Loss for the period	**-28 893**	**-22 911**	**-53 383**	**-43 592**	**-96 854**	**-87 063**
Net Profit/Loss attributable to:						
Parent company shareholders	-28 893	-22 911	-53 383	-43 592	-96 854	-87 063
Earnings per share based on Net Profit/loss attributable to parent company shareholders (in SEK/share)						
Profit/loss per share (before and after dilution)**	-2,83	-6,77	-5,80	-13,69	-14,64	-24,16
Average number of shares outstanding	10 225	3 383	9 211	3 185	6 617	3 604

**See Note 1 Accounting Principles regarding restatements*

***Recalculated for in June 2026 performed reverse split 1:100. Profit/loss per share after dilution is not reported, since this would imply improved earnings per share.*

Consolidated summary statement of comprehensive income

SEK 000'	Apr 1 - June 30 2026	Apr 1 - June 30 2025*	Jan 1 - June 30 2026	Jan 1 - June 30 2025*	July 1, 2025 - June 30, 2026 Rolling-12	Jan 1 - Dec 31 2025
Profit/loss for the period	-28 893	-22 911	-53 383	-43 592	-96 854	-87 063
Other comprehensive income for the period:						
Items that have or may be reclassified to profit or loss:						
Translation differences on foreign operations	1 000	1 304	675	1 056	61	442
Sum other comprehensive income	**1 000**	**1 304**	**675**	**1 056**	**61**	**442**
Total comprehensive income for the period	**-27 893**	**-21 606**	**-52 708**	**-42 536**	**-96 793**	**-86 621**
Total comprehensive income attributable to:						
Parent company shareholders	-27 893	-21 606	-52 708	-42 536	-96 793	-86 621

Consolidated summary statement of financial position

	June 30		Dec 31
SEK 000'	2026	2025	2025
ASSETS			
Fixed Assets			
Tangible fixed assets	1 273	1 241	1 095
Right of use assets	3 369	2 917	3 138
Financial fixed assets	0	0	0
Total Tangible Assets	4 642	4 158	4 233
Current Assets			
Inventory	14 011	9 242	9 268
Current tax receivable	1 026	964	660
Receivables	13 390	12 188	11 854
Other current receivables	2 760	2 342	3 549
Cash equivalents	37 153	23 958	22 604
Total Current Assets	68 341	48 695	47 936
Total Assets	72 983	52 853	52 169
Shareholders' Equity and Liabilities			
Shareholders' equity attributable to parent company shareholders	30 221	32 299	6 656
Longterm Liabilities			
Long-term lease liabilities IFRS-16	1 499	577	540
Loan	20 000	0	20 000
Total Longterm Liabilities	21 499	577	20 540
Current Liabilities			
Accounts payable	7 648	6 761	5 544
Short-term lease liabilities (IFRS-16)	1 709	2 224	2 489
Other current liabilities	11 907	10 992	16 940
Total Current Liabilities	21 263	19 977	24 973
Total Liabilites	42 762	20 554	45 513
Total shareolders' equity and liabilities	72 983	52 853	52 169

Consolidated change in shareholders' equity

SEK 000'	Share Capital	Other Capital Contributions	Accumulated Loss	Total shareholders' Equity attributable to parent company shareholdlers
Opening balance Jan 1, 2025	10 977	760 102	-734 429	36 651
Profit/loss for the period			-43 592	-43 592
Other comprehensive income		0	1 056	1 056
Total comprehensive income	0	0	-42 536	-42 536
Transactions with shareholders:				
New share issue	5 938	47 503		53 441
Issue expenses		-3 952		-3 952
At the end of 2024 ongoing share issue		-12 704	0	-12 704
Total transactions with shareholders	5 938	30 847	0	36 785
Closing balance June 30, 2025	16 915	790 949	-776 964	30 899
Opening balance Jan 1, 2026	20 709	806 996	-821 049	6 656
Profit/loss for the period			-53 383	-53 383
Other comprehensive income		-185	860	675
Total comprehensive income	0	-185	-52 523	-52 708
Transactions with shareholders:				
New share issue	30 417	49 437		79 854
Issue expenses		-3 581		-3 581
Total transactions with shareholders	30 417	45 856	0	76 274
Closing balance June 30, 2026	51 127	852 668	-873 573	30 221

Consolidated summary statement of cash flows

	Apr 1 - June 30		Jan 1 - June 30		July 1, 2025 - June 30, 2026	Jan 1 - Dec 31
SEK 000'	2026	2025	2026	2025	Rolling-12	2025
Cashflow from operating activities before change in working capital	-26 773	-20 579	-50 103	-40 991	-92 615	-83 503
Cashflows from changes in working capital						
Change in Inventory	-4 279	-1 430	-4 743	-922	-4 769	-948
Change in Receivables	485	-2 408	-1 113	-1 021	-1 682	-1 590
Change in Liabilities	-2 528	3 952	-3 710	-3 534	1 286	1 462
Total change in working capital	*-6 322*	*114*	*-9 566*	*-5 476*	*-5 165*	*-1 076*
Cashflow from operating activities	-33 095	-20 466	-59 669	-46 467	-97 780	-84 579
Investment activities						
Acquisitions of Fixed Assets	-414	91	-414	91	-732	-228
Cashflow from investment activities	-414	91	-414	91	-732	-228
Financing activities						
New share issues	0	11 200	79 854	64 641	99 009	83 796
Expenses related to new share issues	0	-298	-3 581	-3 952	-4 294	-4 665
Loan	0	-	0	-	20 000	20 000
Repayment of lease liabilities	-719	-703	-1 431	-1 379	-2 891	-2 839
Cashflow from financing activities	-719	10 199	74 843	59 310	111 824	96 292
Cashflow for the period	-34 228	-10 176	14 761	12 934	13 312	11 485
Cash equivalents at start of the year	71 255	34 295	22 603	11 245	23 958	11 245
Exchange rate differences in cash equivalents	124	-161	-212	-220	-118	-127
Cash equivalents at end of the period	37 152	23 958	37 152	23 958	37 152	22 604

Income statement, Parent Company

SEK 000'	Apr 1 - June 30 2026	Apr 1 - June 30 2025	Jan 1 - June 30 2026	Jan 1 - June 30 2025	July 1, 2025 - June 30, 2026 Rolling-12	Jan 1 - Dec 31 2025
Net Sales	1 186	1 186	2 372	2 372	4 744	4 744
Gross profit	**1 186**	**1 186**	**2 372**	**2 372**	**4 744**	**4 744**
Administration expenses	-3 512	-2 876	-7 314	-6 427	-14 957	-14 071
Other Income	0	0	0	0	0	0
Other expenses	0	0	-4	1	-4	1
Operating Profit/loss	**-2 326**	**-1 690**	**-4 946**	**-4 054**	**-10 217**	**-9 326**
Earnings from financial items:						
Profit/Loss from shares in group companies	-9 170	-16 889	-20 602	-32 492	-144 187	-156 076
Financial income	7	0	9	122	165	277
Financial expenses	-209	0	-418	0	-530	-112
Profit/loss after financial items	**-11 698**	**-18 579**	**-25 956**	**-36 425**	**-154 769**	**-165 238**
Taxes	-	-	-	-	-	-
Profit/loss for the period	**-11 698**	**-18 579**	**-25 956**	**-36 425**	**-154 769**	**-165 238**

Statement of other comprehensive income, Parent Company

SEK 000'	Apr 1 - June 30 2026	Apr 1 - June 30 2025	Jan 1 - June 30 2026	Jan 1 - June 30 2025	July 1, 2025 - June 30, 2026 Rolling-12	Jan 1 - Dec 31 2025
Profit/loss for the period	-11 698	-18 579	-25 956	-36 425	-154 769	-165 238
Other comprehensive income	-	-	-	-	-	-
Total other comprehensive income	-	-	-	-	-	-
Total comprehensive income	-11 698	-18 579	-25 956	-36 425	-154 769	-165 238

Summary Balance Sheet, Parent Company

	June 30		Dec 31
SEK 000'	2026	2025	2025
ASSETS			
Fixed Assets			
Shares in Group Companies	137 647	137 647	137 647
Total Fixed Assets	**137 647**	**137 647**	**137 647**
Current Assets			
Current receivables and prepaids	38 981	88 648	6 059
Cash equivalents	25 732	15 820	9 300
Total Current Assets	**64 713**	**104 468**	**15 359**
TOTAL ASSETS	202 360	242 115	153 005
SHAREHOLDERS' EQUITY AND LIABILITIES			
Shareholder's equity			
Restricted equity			
Share capital	51 127	18 315	20 709
Non-restricted equity			
Other capital contributions	852 550	790 832	806 879
Retained earnings	-698 699	-533 462	-533 462
Profit/Loss for the period	-25 956	-36 425	-165 238
Shareholders equity	**179 021**	**239 260**	**128 889**
Long-term liabilites			
Loan	20 000	-	20 000
Current Liabilities			
Current liabilities	3 338	2 855	4 116
Total liabilities	**23 338**	**2 855**	**24 116**
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES	202 360	242 115	153 005

Notes

Note 1 Accounting principles

The Group's interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Annual Accounts Act. For the Parent Company, the interim report has been prepared in accordance with the Annual Accounts Act and the Swedish Securities Market Act in accordance with the provisions of RFR 2. For both the Group and the Parent Company the same accounting principles and bases for calculation have been applied as in its most recent Annual Report with the exception of what is stated below. Significant accounting and valuation principles are detailed on pages 54-60 of the consolidated annual report for 2025. The Group's lending to the wholly owned American subsidiary SciBase Inc. constitutes part of the net investment in the foreign operation as of 2025 in accordance with IAS 21 p. 15. The background is that the receivable in practice constitutes an extension of the parent company's net investment in the subsidiary, as settlement of the receivable is neither planned nor probable in the foreseeable future. Exchange rate differences that arise when translating the receivable to the closing rate are therefore reported in other comprehensive income and accumulated in the translation reserve in equity, instead of being reported as financial income/expense in the income statement. The change has been applied retroactively and all presented comparative figures have been restated in accordance with IAS 8.

Note 2 Fair value of financial instruments

Current receivables and liabilities

For current receivables and liabilities, such as accounts receivable and accounts payable with a maturity of less than six months, the carrying amount is considered to reflect fair value.

Note 3 Contingent Liabilities

The Parent Company issued a capital adequacy guarantee to its wholly owned subsidiary SciBase AB to secure that the equity at minimum corresponds to the share capital that is valid until the end of 2024. A corresponding agreement was in-place in 2023, 2022, 2021, 2020, 2019, 2018, 2017, 2016, 2015 and 2014 as well.

Note 4 Seasonal effects

To a certain extent, SciBase's sales and operating profit are expected to be dependent on seasonal variation that the company cannot influence. In the third quarter, due to the vacation period, the number of tests performed is expected to decrease and consequently the company's sales are also expected to dip.

Note 5 Information regarding operating segments

The Group has today two operating segments, skin cancer and skin barrier assessment. Follow-ups are in addition done on the geographical areas, Europe, US/North America and Asia/Oceania.

Second quarter

Skin cancer

Europe

Net sales during the period amounted to TSEK 6,574 (5,648) of which Germany accounted for 99 (98)%. In the period the focus for the sales and marketing effort has continued to be Germany with the Company's own sales organization and to some extent geographic expansion. Gross profit amounted to a profit of TSEK 4,367 (3,393).

Other geographical areas

Net sales during the period amounted to TSEK 5,461 (3,038). The sales consisted mainly of electrode sales to dermatology practices in the US. Gross profit amounted to TSEK 3,878 (2,365).

The Group has chosen to merge the areas US/North America and Asia/Oceania into Other geographical areas since they presently do not amount to a substantial portion of the total.

Skin barrier assessment

Europe

Net sales during the period amounted to TSEK 43 (59). Gross profit amounted to a profit of TSEK 25 (38). The sales were to researchers within the skin barrier field.

Other geographical areas

Net sales during the period amounted to TSEK 3,230 (46). Gross profit amounted to TSEK negative 220 (positive 26). The sale primarily relates to final deliveries of product to Castle Biosciences (a t a very low/negative margin) for a clinical study and sales to researchers within the field of skin barrier function.

The Group has chosen to merge the areas US/North America and Asia/Oceania into Other geographical areas since they presently do not amount to a substantial portion of the total.

First half-year

Skin cancer

Europe

Net sales during the period amounted to TSEK 12,506 (11,550) of which Germany accounted for 98 (98)%. In the period the focus for the sales and marketing effort has continued to be Germany with the Company's own sales organization and to some extent geographic expansion. Gross profit amounted to a profit of TSEK 7,464 (7,302).

Other geographical areas

Net sales during the period amounted to TSEK 10,334 (5,765). The sales consisted mainly of electrode sales to dermatology practices in the US. Gross profit amounted to TSEK 7,684 (4,560).

The Group has chosen to merge the areas US/North America and Asia/Oceania into Other geographical areas since they presently do not amount to a substantial portion of the total.

Skin barrier assessment

Europe

Net sales during the period amounted to TSEK 91 (287). Gross profit amounted to a profit of TSEK 32 (177). The sales were to researchers within the skin barrier field.

Other geographical areas

Net sales during the period amounted to TSEK 6,655 (46). Gross profit amounted to TSEK negative 104 (positive 26). The sale primarily relates to continued deliveries of product to Castle Biosciences (a t a very low/negative margin) for a clinical study and sales to researchers within the field of skin barrier function.

The Group has chosen to merge the areas US/North America and Asia/Oceania into Other geographical areas since they presently do not amount to a substantial portion of the total.

Note 6 Incentive program

The Group has one incentive program connected to warrants specifically for employees in the US. The Board considers it important and positive if the employees' ownership in the company increases. The Board has evaluated different incentive programs that could include all employees and following this decided to implement a normal bonus program. The goals are set by the board and normally consist of turnover goals and other strategic goals. After the end of the year, it is then assessed how well the goals have been met. However, the purpose of the program is to increase the employees' ownership in the company. The board sees increased ownership by the employees as positive as it increases the employees' incentive for the company to succeed through, for example, increased sales and thereby creating increased shareholder value. Thus, if the employee undertakes to buy shares over the market and enters into a lockup agreement (12-months), the bonus is increased by 4 times the cash bonus. The program has a maximum ceiling (including social security fees etc of SEK 3 million). For 2025 the total cost for the program was approximately MSEK 2.8 (1.6), The outcome of the program is dependent upon reaching the set targets.

Operating segments

	Apr 1 - June 30, 2026			Apr 1 - June 30, 2025		
SEK 000'	Europe	Rest of the World	Total	Europe	Rest of the World	Total
Skincancer - Net sales	6 574	5 461	12 034	5 648	3 038	8 686
The skin barrier function - Net Sales	43	3 230	3 273	59	46	106
Net sales from external customers	6 617	8 691	15 308	5 707	3 084	8 791
Cost of goods - Skincancer	-2 207	-1 583	-3 790	-2 255	-673	-2 928
Cost of goods - Barrier function	-18	-3 450	-3 468	-22	-20	-42
Cost of goods - total	-2 225	-5 033	-7 258	-2 277	-693	-2 970
Gross Profit - Skincancer	4 367	3 878	8 245	3 393	2 365	5 758
Gross Profit - Barrier function	25	-220	-195	38	26	64
Gross Profit - total	4 392	3 657	8 050	3 430	2 391	5 822
Operating expenses			-36 878			-28 180
Operating profit/Loss			-28 828			-22 358
Financial Income			187			-503
Financial Expenses			-252			-50
Group earnings - before tax			-28 893			-22 910

SEK 000'	Jan 1 - June 30, 2026 Europe	Jan 1 - June 30, 2026 Rest of the World	Jan 1 - June 30, 2026 Total	Jan 1 - June 30, 2025 Europe	Jan 1 - June 30, 2025 Rest of the World	Jan 1 - June 30, 2025 Total
Skincancer - Net sales	12 506	10 334	**22 840**	11 550	5 765	**17 315**
The skin barrier function - Net Sales	91	6 655	**6 746**	287	46	**333**
Net sales from external customers	**12 597**	**16 988**	**29 586**	**11 837**	**5 811**	**17 648**
Cost of goods - Skincancer	-5 043	-2 650	**-7 693**	-4 248	-1 206	**-5 453**
Cost of goods - Barrier function	-59	-6 759	**-6 818**	-110	-20	**-131**
Cost of goods - total	**-5 102**	**-9 409**	**-14 511**	**-4 358**	**-1 226**	**-5 584**
Gross Profit - Skincancer	7 464	7 684	**15 147**	7 302	4 559	**11 861**
Gross Profit - Barrier function	32	-104	**-73**	177	26	**203**
Gross Profit - total	**7 495**	**7 579**	**15 075**	**7 479**	**4 585**	**12 064**
Operating expenses			**-68 356**			**-54 000**
Operating profit/Loss			**-53 281**			**-41 936**
Financial Income			**440**			**-1 560**
Financial Expenses			**-542**			**-96**
Group earnings - before tax			**-53 383**			**-43 592**

Net sales per category and segment

Amounts in KSEK	Apr 1 - June 30 2026 Europe	Apr 1 - June 30 2026 Rest of the World	Apr 1 - June 30 2025 Europe	Apr 1 - June 30 2025 Rest of the World	Jan 1 - June 30 2026 Europe	Jan 1 - June 30 2026 Rest of the World	Jan 1 - June 30 2025 Europe	Jan 1 - June 30 2025 Rest of the World	Rolling-12 Europe	Rolling-12 Rest of the World	Full Year 2025 Europe	Full Year 2025 Rest of the World
Skin cancer												
Electrodes	6 271	5 141	5 429	2 631	11 670	9 237	10 890	4 987	25 398	15 577	24 618	11 328
Instruments	303	320	219	407	836	1 097	660	778	846	2 087	669	1 768
Total Skin Cancer	**6 574**	**5 461**	**5 648**	**3 038**	**12 506**	**10 334**	**11 550**	**5 765**	**26 243**	**17 665**	**25 287**	**13096**
Skin barrier function												
Electrodes	43	1 705	59	46	67	2 832	205	46	294	3 513	433	727
Instruments	0	1 525	0	0	24	3 823	82	0	91	4 592	149	769
Total skin barrier function	**43**	**3 230**	**59**	**46**	**91**	**6 655**	**287**	**46**	**386**	**8 105**	**582**	**1497**
Total												
Electrodes	6 314	6 845	5 489	2 677	11 737	12 069	11 095	5 033	25 692	19 091	25 051	12 055
Instruments	303	1 845	219	407	860	4 920	742	778	937	6 679	818	2 537
Total	**6 617**	**8 691**	**5 708**	**3 084**	**12 597**	**16 988**	**11 837**	**5 811**	**26 629**	**25 770**	**25 869**	**14 593**

Signatures

The Board of Directors and the President provide their assurance that this interim report provides an accurate view of the operations, position and earnings of the Group and the Parent Company, and that it also describes the principal risks and uncertainties faced by the Parent Company and the companies included within the Group.

(SciBase Holding AB)
Stockholm, August 19, 2026

Jesper Høiland
Chairman of the Board

Diana Ferro
Board member

Robert Molander
Board member

Anna Eriksrud
Board member

Pia Renaudin
CEO

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on August 19, 2026.

This year-end report has not been subject to review by the Company's auditors

This report, together with previously published interim reports, can be found in its entirety on the company's website: http://investors.scibase.se/en/reports-and-presentations

Contact person:
Michael Colérus, CFO, +46 70 341 34 72

Quarterly overview

	2026		2025				2024		
THE GROUP	Q2	Q1	Q4	Q3	Q2	Q1	Q4	Q3	Q2
Net sales, SEK ths	15 308	14 278	12 475	10 339	8 791	8 856	8 598	8 408	6 641
Gross margin, %	52,6%	49,2%	63,0%	69,5%	66,2%	70,5%	68,5%	75,7%	69,1%
Equity/Asset ratio, %	41,4%	56,0%	12,8%	62,0%	61,1%	71,6%	59,4%	67,6%	71,8%
Net indebtness, multiple	2,13	1,16	6,84	0,61	0,64	0,40	0,68	0,48	0,39
Cash equivalents, SEK ths	37 153	71 255	22 604	24 757	23 958	34 295	11 245	24 714	43 271
Cashflow from operating activities, SEK ths	-33 095	-26 573	-20 824	-17 287	-20 466	-26 001	-12 548	-16 475	-15 179
Earnings per share (before and after dilution), SEK*	-2,83	-2,99	-6,11	-4,66	-6,77	-6,92	-9,87	-8,09	-8,08
Shareholder's equity per share, SEK*	2,96	7,09	1,61	8,58	9,55	14,40	16,69	17,26	28,39
Average number of shares, 000'*	10 225	8 197	4 142	3 902	3 383	2 987	2 195	2 195	1 863
Number of shares at closing of period, 000'*	10 225	10 225	4 142	4 142	3 663	3 383	2 195	2 195	2 195
Share price at end of period, SEK*	32,50	35,00	29,00	38,00	38,00	42,00	41,00	48,00	51,00
Number of sold electrodes, pieces	40 144	30 460	28 634	21 278	18 398	17 870	17 132	17 210	14 016
Average number of employees	51	46	43	34	35	35	30	29	27

**Recalculated for in June 2026 performed reversed split, 100:1*

Definitions

Financial key ratios

- **TSEK**: SEK 000'
- **Gross margin, %:** Gross profit divided by net sales.
- **Operating profit:** Operating income less operating expenses.
- **Operating margin, %:** Operating profit divided by income.
- **Equity/assets ratio:** Equity at the end of the period divided by total assets at the end of the period.
- **Debt/equity ratio:** Total liabilities in relation to equity.
- **Earnings per share for the period before dilution:** Profit for the period divided by average number of shares before dilution.
- **Earnings per share for the period after dilution:** Profit for the period divided by average number of shares after dilution. Earnings per share after dilution is the same as before dilution because potential ordinary shares do not cause dilution.
- **Shareholders' equity per share:** Equity divided by average number of shares.
- **Dividend per Share:** Dividend for the period divided by average number of shares after dilution.
- **Number of shares before dilution at the end of the period:** Number of shares in issue before dilution at the end of the period.
- **Average number of shares before dilution:** Average number of shares during the period before dilution.
- **Average number of shares after dilution:** Average number of shares in issue after dilution is the same as before dilution because potential ordinary shares do not cause dilution.
- **Number of employees (average):** Weighted average number of employees in the relevant period.
- **IFRS:** International Financial Reporting Standards

Industry specific glossary

- **CE labeling:** A mandatory conformity marking to show that products sold within the European Economic Area (EEA) since 2008 fulfills the requirements of the acquis. CE labeling is also included on products sold outside the EEA but that are produced in the EEA or intended for sale there.
- **Dermatoscopy or Dermoscopy:** Examination of skin lesions with a dermatoscope, a strong magnifying glass with a built-in light source.
- **Electrical Impedance Spectroscopy (EIS):** A measure of the overall impedance occurring in tissue when alternating current is applied at a series of alternating frequencies. This is measured by transmitting an imperceptible alternating current between the bands on the electrode, which is mounted on the tip of the probe and measures the current.
- **FDA:** The US Food and Drug Administration is the US authority controlling all aspects of the development, manufacture and commercialization of pharmaceutical products and medical devices in the United States.
- **Melanoma:** The most dangerous form of skin cancer, consisting of cancer in pigment-producing melanocytes.
- **Unnecessary excision:** The removal of benign skin lesions/birthmarks.
- **Nevi:** Lesions.
- **PMA:** Pre-Market Approval, a form of approval from the US FDA required for all new Class III devices.

Alternative performance measures (APM)

This section contains a reconciliation of certain alternate performance measures (APM) against the most reconcilable items in the financial statements. The reporting of APMs has limitations as analytical tools and should not be viewed without context or as compensation for financial measures prepared in accordance with IFRS. APMs are reported to improve investors' evaluation of ongoing operating profit, as a means of predicting future periods, and to simplify a meaningful comparison of results between periods. Management uses these APMs to evaluate, among other things, ongoing operations compared with previous results, for internal planning and forecasting, as well as for calculation of certain performance-related compensation. The APMs reported in this interim report may differ from measures with similar terms used by other companies.

APM for the period:

Gross Margin (%)

	2026	2025	Definition:	Cause of use:
Gross Profit	15 075	12 064	Gross Profit / Loss divided with Net Sales.	The gross margin shows the difference betweend net sales and the cost of goods sold in % of net sales. The gross margin is affected by several factors such as productmix, price trends, exchange rate fluctuation, efficiency in manufactruing processess etc. This is an important measurement as it provides a better understanding of the Company's progress.
Net Sales	29 586	17 648		
Gross Margin (%)	**51,0%**	**68,4%**		

Shareholder Equity ratio (%)

	2026	2025	Definition:	Cause of use:
Total Shareholders' Equity	30 221	32 299	Total Shareholders' Equity at the end of the period divided with Total Assets at the end of the year.	Shareholders equity ratio shows the Group's financial sustainability and the portion that is financed by equity.
Total Assets	72 983	52 853		
Shareholders' Equity ratio (%)	**41,4%**	**61,1%**		

Debt ratio (times)

	2026	2025	Definition:	Cause of use:
Total Liabilities	42 762	20 554	Total debt in relation to Total Shareholders' Equity.	The debt ratio indicates how much debt the Company is using to finance its assets relative to the value of of shareholders' equity. It is closely connected to the Shareholder's equity ratio.
Total Sharholders´Equity	30 221	32 299		
Debt ratio (times)	**1,41**	**0,64**		

Earnings per share, after dilution (sek)

	2026	2025	Definition:	Cause of use:
Profit/Loss for the period	-53 383	-43 592	Is the portion of a company's profit allocated allocated to each outstanding share of common stock after dilution. The result per share after the dilution is no different than before the dilution due to that potential common stock do not give rise to a dilution effect.	This shows the value per share.
Average nu,ber of shares (thousand)	9 211	3 185		
Earnings per share (sek)	**-5,80**	**-13,69**		

Shareholders' equity per share (sek)

	2026	2025	Definition:	Cause of use:
Shareholders' Equity	30 221	32 299	Shareholders' equity divided with the average number of shares after dilution	The shareholders' equity per share provides a measure of the net worth per share and can be set in relation to the actual stock price
Average number of shares (thousand)	9 211	3 185		
Shareholders' equity per share	**3,28**	**10,14**		

Average number of shares (thousand)

	2026	2025	Definition:	Cause of use:
Opening balance - Jan 1	4 142	2 195	The aveage number of issued shares.	The average number of shares gives a more accurate picture of the result and shareholders' equity due to the fact that the number of shares can change.
Closing balance - December 31	10 225	3 383		
Average number of shares (thousand)	**9 211**	**3 185**		

Pia Renaudin
CEO
+46 73 206 98 02
pia.renaudin@scibase.com

Read more about the company and its operations at our website >> www.scibase.com

Michael Colérus
CFO
+46 70 341 34 72
michael.colerus@scibase.com

Future reporting dates

Interim report Q3, November 12, 2026

Year-end report 2026, February 2027